checkpoint inhibitor

Overview

Immune checkpoint inhibitors (ICIs) are a class of immunotherapeutic agents that block inhibitory regulatory proteins expressed on T cells or tumor cells, thereby restoring or amplifying endogenous antitumor immune responses. The principal molecular targets include programmed cell death protein 1 (PD-1) and its ligand PD-L1, as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) — both of which normally serve as physiological "brakes" that prevent excessive immune activation. Under oncogenic conditions, tumors exploit these checkpoints to escape immune surveillance, rendering cytotoxic T cells functionally exhausted or tolerant. Agents such as pembrolizumab, nivolumab, durvalumab, camrelizumab, cemiplimab, atezolizumab, and the dual CTLA-4/PD-1 combination of durvalumab plus tremelimumab have each been developed to disrupt these inhibitory axes. Additional emerging targets include TIGIT and CD276 (B7-H3), expanding the checkpoint landscape. By removing suppressive signals, ICIs enable the tumor microenvironment (TME) to shift toward a more immunologically active state, characterized by increased cytotoxic T cell infiltration, proinflammatory cytokine secretion (including IFNG and interleukin-6), and macrophage repolarization, which collectively drive tumor regression.

Since their early clinical adoption, ICIs have redefined standard-of-care across multiple solid tumors and are increasingly investigated in combination with chemotherapy, radiation, Targeted therapies, antibody-drug conjugates, bispecific T cell engagers, vaccines, and adoptive cell therapies. Despite their transformative impact, durable responses occur in only a minority of patients across most tumor types, and immune-related adverse events (irAEs) — ranging from colitis and hepatitis to nephritis, myasthenia gravis overlap syndrome, bullous pemphigoid, esophagitis, optic neuritis, and endocrinopathies — present significant clinical management challenges.

Role in Recent Research

Recent publications portray checkpoint inhibitors as both a mature therapeutic platform and an active area of biomarker-driven refinement. Several studies focused on predicting response using multi-omics, single-cell RNA-seq, spatial transcriptomics, transcriptomics, proteomics, radiomics, liquid biopsy, machine learning, and artificial intelligence. For example, lung adenocarcinoma and non-small cell lung cancer studies used single-cell and spatial profiling, blood-based kinase activity profiling, and AI-based histopathology to stratify likely responders. Other work examined immune states in gastric cancer ascites, tertiary lymphoid structures in gastric cancer and Merkel cell carcinoma, conventional type-1 dendritic cell density across multiple cancers, and blood immune cell profiles in metastatic disease. Across these reports, the recurring conclusion was that checkpoint inhibitor benefit is strongly shaped by the tumor immune microenvironment and that reliable predictive biomarkers remain a major unmet need.

A substantial portion of the recent literature addressed mechanisms of resistance to immune checkpoint blockade. Investigators reported associations between poor response and features such as immunologically cold tumors, suppressive myeloid programs, altered macrophage polarization, ferroptosis resistance, cuproptosis-ferroptosis resistance, replication stress pathways, HLA class I loss, STK11 mutation, Aurora kinase A signaling, and aberrant alternative splicing. Several studies proposed that targeting pathways such as DGAT1, RNase H2, CRTC2, EFHD2, FOXM1, or the cGAS-STING axis may sensitize tumors to checkpoint blockade. Others explored combination strategies involving RAS inhibitors, Cdk4/6 inhibition with palbociclib, anti-VEGFR-2/PD-1 therapy, anti-PD-L1 with proton radiation or hyperthermia, localized NOD2/STING activation, intratumoral nucleoside cleavage, and microbiome-directed interventions such as fecal microbiota transplantation. Collectively, these studies reinforce the view that checkpoint inhibitors are often most effective when paired with therapies that increase antigenicity, T-cell infiltration, or inflammatory signaling.

Multiple reports examined clinical outcomes in specific cancers treated with checkpoint inhibitor-based regimens. In metastatic renal cell carcinoma, studies evaluated first-line immune checkpoint inhibitor combinations, early tumor shrinkage, rechallenge outcomes, and the influence of aging or concomitant medications. In hepatocellular carcinoma, checkpoint inhibitors were studied in neoadjuvant settings, combined with tyrosine-kinase inhibitors, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and carbon-ion radiotherapy, as well as in the context of liver transplantation and post-transplant rejection risk. In gastric and gastroesophageal junction cancer, real-world treatment patterns, sequencing with chemotherapy, and biomarker-selected use were reported. In cervical cancer, checkpoint inhibitors such as pembrolizumab, cemiplimab, camrelizumab, and avelumab maintenance were associated with improved survival in real-world and trial-based settings. Additional studies described activity in bladder cancer, anal cancer, esophageal squamous cell carcinoma, pleural mesothelioma, melanoma, nasopharyngeal carcinoma, prostate cancer, and pediatric solid tumors, while also emphasizing that responses remain inconsistent outside molecularly defined subsets such as dMMR/MSI-H or hypermutated tumors.

The recent literature also highlights the toxicity profile of checkpoint inhibitors, especially immune-related adverse events (irAEs). Several studies focused on immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, myasthenia gravis-myositis overlap syndrome, optic neuritis, neurotoxicity, colitis, hepatitis, esophagitis, bullous pemphigoid, nephritis, thyroid dysfunction, adrenal insufficiency, autoimmune hemolytic anemia, and cardiotoxicity. Real-world cohorts and bibliometric analyses emphasized that cardiovascular and neurologic toxicities can be severe or fatal, and that rechallenge after toxicity requires careful risk assessment. Other work examined the interaction of checkpoint inhibitors with pre-existing autoimmune disease, baseline thyroid autoantibodies, clonal hematopoiesis, and concomitant medications. These studies collectively underscore that while checkpoint blockade can be highly effective, its immune activation can also produce clinically significant off-target inflammation in normal tissues.

A further theme is the expansion of checkpoint inhibitors into multimodal treatment strategies. Recent studies investigated combinations with chemotherapy, anti-angiogenic therapy, tyrosine-kinase inhibitors, radiotherapy, proton radiation, hyperthermia, sonodynamic therapy, nanomedicine, engineered bacteria, exosome-based platforms, and biomimetic nanodecoys. In thoracic oncology, checkpoint inhibitors were studied in neoadjuvant and consolidation settings for non-small cell lung cancer, including sequencing questions and postoperative safety. In urothelial carcinoma, maintenance avelumab and other checkpoint-based regimens were evaluated in real-world cohorts. In breast cancer, bladder cancer, colorectal cancer, and glioblastoma, multiple preclinical studies sought to overcome immune exclusion and improve checkpoint inhibitor efficacy through metabolic reprogramming, macrophage repolarization, or enhanced local immune activation. Overall, the recent research landscape presents checkpoint inhibitors as foundational agents whose clinical value increasingly depends on biomarker selection, rational combination therapy, and proactive toxicity management.

Key Publications

• NEWJul Single-cell and machine learning-based neural regulation signature for prognosis prediction and immunotherapy response in lung adenocarcinoma. (Translational oncology, 2026, PMID 42391672): "to precisely assess prognosis and guide personalized immunotherapy."
• NEWJul GPX1 Drives Cuproptosis-Ferroptosis Resistance in Cold Tumors. (Free radical biology & medicine, 2026, PMID 42392283): "...highlight the SLC7A11-UMPs-GPX1 axis as a promising therapeutic target for overcoming treatment resistance and enhancing immunotherapy response."
• NEWJul Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. (Immunologic research, 2026, PMID 42384108): "Checkpoint inhibitors, a class of immunotherapeutic agents, have transformed the oncology landscape by targeting immune checkpoints - regulatory pathways that modulate immune cell activity."
• NEWJul Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study. (International journal of urology : official journal of the Japanese Urological Association, 2026, PMID 42385189): "Combination therapies incorporating immune checkpoint inhibitors (ICIs) are widely used as first-line treatment for metastatic renal cell carcinoma (mRCC)."
• Jul The Impact of Immunotherapy on Hair Repigmentation in Patients With Thoracic Tumors: A Clinical Observation Based on Trichoscopy. (Thoracic cancer, 2026, PMID 42387269): "Whether hair repigmentation during cancer therapy is driven by immune checkpoint inhibitors (ICIs) or chemotherapy remains unclear."
• Jul Deciphering the Therapeutic and Preventive Potential of Dietary Tannins in Osteosarcoma: A Multi-Omics Approach Targeting TGFA and Immune Microenvironment Remodeling. (Food science & nutrition, 2026, PMID 42375570): "Furthermore, immunotherapy prediction tools suggested a lower likelihood of response to immune checkpoint blockade in the high-TRR group."
• Jul Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpoint inhibitor era. (Journal of managed care & specialty pharmacy, 2026, PMID 42341069): "Since 2021, new therapies including immune checkpoint inhibitors (ICIs) have been approved in the United States for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction cancer (G/GEJC) in biomarker-selected populations."
• Jul HIV Infection and Opioid Treatment Enable the Engraftment of Kaposi Sarcoma-Like Tumors Into Immunocompetent Mice. (Journal of medical virology, 2026, PMID 42370728): "This novel KSHV tumor model in immunocompetent mice provides a valuable platform to test immunotherapeutic strategies for KS, including immunomodulatory agents, targeted antibody therapies, checkpoint inhibitors, and vaccines."
• Jul Feasibility Study of Combined Systemic Therapy and Carbon-Ion Radiotherapy for Hepatocellular Carcinoma Patients. (Cancer medicine, 2026, PMID 42363399): "Recent advances in systemic therapy, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have improved outcomes for hepatocellular carcinoma (HCC) and enabled downstaging strategies that allow subsequent local treatments."
• May The role of microRNAs and competing endogenous RNA regulatory networks in mesothelioma response to immunotherapy. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 42177870): "...in response to treatment with immune checkpoint inhibitors (ICI) within the context of competing endogenous RNA (ceRNA) networks."